参考文献/References:
［1］ Von THUN UND HOHENSTEIN-BLAUL N，FUNKE S，GRUS FH.Tears as a source ofbiomarkers for ocular and systemic diseases［J］.Exp Eye Res，2013，117（7）：126-137.
［2］ 高妍，刘新玲，李筱荣.糖尿病患者眼表及泪液蛋白改变的临床分析［J］.眼科新进展，2011，31（3）：267-270.
GAO Y,LIU XL，LI XR.Clinical analysis of ocular surface and tear film changes in type 2 diabetes mellitus［J］.Rec Adv Ophthalmol，2011，31（3）：267-270.
［3］ YOU J，WILLCOX MD，MADIGAN MC，WASINGER V，SCHILLER B，WALSH BJ，et al.Tear fluid protein biomarkers［J］.Adv Clin Chem，2013，62（62）：151-196.
［4］ PIERAGOSTINO D，D’ALESSANDOR M，DI IOIA M，DI ILIO C，SACCHETTA P，DEL BOCCIO P.Unraveling the molecular repertoire of tears as a source of biomarkers：beyond ocular diseases［J］.Prot Clin Appl，2015，9（1-2）：169-186.
［5］ 高丽涛，柳力敏，张媛媛，刘磊，胡悦东，陈蕾.糖尿病视网膜病变的危险因素分析［J］.眼科新进展，2011，31（8）：742-744.
GAO LT,LIU LM,ZHANG YY,LIU L,HU YD,CHEN L.Risk factors analysis of diabetic retinopathy［J］.Rec Adv Ophthalmol，2011，31（8）：742-744.
［6］ VUJOSEVIC S，MICERA A，BINI S，BERTON M，ESPOSITO G，MIDENA E.Proteomeanalysis of retinal glia cells-related inflammatory cytokines in the aqueoushumour of diabetic patients［J］.Acta Ophthalmol，2016，94（1）：56-64.
［7］ CHEUNG CM，VANIA M，ANG M，CHEE SP，LI J.Comparison of aqueous humor cytokine and chemokine levels in diabetic patients with and without retinopathy［J］.Mol Vis，2012，18：830-837.
［8］ DONG N，SHI H，XU B，CAI Y.Increased plasma S100A12 levels are associated with diabetic retinopathy and prognostic biomarkers of macrovascular events in type 2 diabetic patients［J］.Invest Ophthalmol Vis Sci，2015，56（8）：4177-4185.
［9］ PARK KS，KIM SS，KIM JC，KIM HC，IM YS，AHN CW，et al.Serum and tear levels of nerve growth factor in diabetic retinopathy patients［J］.Am J Ophthalmol，2008，145（3）：432-437.
［10］ CSOSZ E，BOROSS P，CSUTAK A，BERTA A，TOTH F，POLISKA S，et al.Quantitative analysis of proteins in the tear fluid of patients with diabetic retinopathy［J］.J Proteomics，2012，75（7）：2196-2204.
［11］ KIM HJ，KIM PK，YOO HS，KIM CW.Comparison of tear proteins between healthy and early diabetic retinopathy patients［J］.Clin Biochem，2012，45（1-2）：60-67.
［12］ COSTAGLIOLA C，ROMANO V，DE TOLLIS M，ACETO F，DELL’OMO R，ROMANO MR，et al.TNF-alpha levels in tears：a novel biomarker to assess the degree of diabetic retinopathy［J］.Mediators Inflamm，2013，2013（9）：629529.
［13］ TOROK Z，PETO T，CSOSZ E，TUKACS E，MOLNAR AM，BERTA A，et al.Combined methods for diabetic retinopathy screening，using retina photographs and tear fluid proteomics biomarkers［J］.J Diabetes Res，2015，2015：623619.
［14］ NGUYEN-KHUONG T，EVEREST-DASS AV，KAUTTO L，ZHAO Z，WILLCOX MD，PACKER N.Glycomic characterization of basal tears and changes with diabetes and diabetic retinopathy［J］.Glycobiology，2015，25（3）：269-283.
［15］ GABRIELLI A，AVVEDIMENTO EV，KRIEG T.Scleroderma［J］.N Engl J Med，2009，360（19）：1989-2003.
［16］ TAILOR R，GUPTA A，HERRICK A，KWARTZ J.Ocular manifestations of scleroderma［J］.Surv Ophthalmol，2009，54（2）：292-304.
［17］ RENTKA A，HARSFALVI J，BERTA A，KOROSKENYI K，SZEKANECZ Z，SZUCS G，et al.Vascular endothelial growth factor in tear samples of patients with systemic sclerosis［J］.Mediators Inflamm，2015，2015（2）：573681.
［18］ RENTKA A，HARSFALVI J，SZUCS G，SZEKANECZ Z，SZODORAY P，KOROSKENYI K，et al.Membrane array and multiplex bead analysis of tear cytokines in systemic sclerosis［J］.Immunol Res，2016，64（2）：619-626.
［19］ O’SULLIVAN BP，FREEDMAN SD.Cystic fibrosis［J］.Lancet，2009，373（9678）：1891-1904.
［20］ MRUGACZ M，KACZMARSKI M，BAKUNOWICZ-LAZARCZYK A，ZELAZOWSKA B，WYSOCKA J，MINAROWSKA A.IL-8 and IFN-gamma in tear fluid of patients with cystic fibrosis［J］.J Interferon Cytokine Res，2006，26（2）：71-75.
［21］ MRUGACZ M，ZELAZOWSKA B，BAKUNOWICZ-LAZARCZYK A，KACZMARSKI M，WYSOCKA J.Elevated tear fluid levels of MIP-1alpha in patients with cystic fibrosis［J］.J Interferon Cytokine Res，2007，27（6）：491-495.
［22］ MRUGACZ M.CCL4/MIP-1beta levels in tear fluid and serum of patients with cystic fibrosis［J］.J Interferon Cytokine Res，2010，30（7）：509-512.
［23］ GRECH G，ZHAN X，YOO BC，BUBNOV R，HAGAN S，DANESI R，et al.EPMA position paper in cancer：current overview and future perspectives［J］.EPMA J，2015，6（1）：1-31.
［24］ HAGAN S，ORR MC，DOYLE B.Targeted therapies in colorectal cancer-an integrative view by PPPM［J］.EPMA J，2013，4（1）：3.
［25］ MANOSROI A，SAINAKHAM M，CHANKHAMPAN C，MANOSROI W，MANOSROI J.In vitro anti-cancer activities of Job’s tears（Coix lachryma-jobi Linn.） extracts on human colon adenocarcinoma［J］.Saudi J Biol Sci，2016，23（2）：248-256.
［26］ ALNAES GI，RONNEBERG JA，KRISTENSEN VN，TOST J.Heterogeneous DNA methylation patterns in the GSTP1 promoter lead to discordant results between assay technologies and impede its implementation as epigenetic biomarkers in breast cancer［J］.Genes（Basel），2015，6（3）：878-900.
［27］ WU SG，HE ZY，REN HY，YANG LC，SUN JY，LI FY，et al.Use of CEA and CA15-3 to predict axillary lymph node metastasis in patients with breast cancer［J］.J Cancer，2016，7（1）：37-41.
［28］ LEBRECHT A，BOEHM D，SCHMIDT M，KOELBL H，GRUS FH.Surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry to detect breast cancer markers in tears and serum［J］.Cancer Genomics Proteomics，2009，6（2）：75-83.
［29］ LEBRECHT A，BOEHM D，SCHMIDT M，KOELBL H，SCHWIRZ RL，GRUS FH.Diagnosis of breast cancer by tear proteomic pattern［J］.Cancer Genomics Proteomics，2009，6（3）：177-182.
［30］ BOHM D，KELLER K，PIETER J，BOEHM N，WOLTERS D，SIGGELKOW W，et al.Comparison of tear protein levels in breast cancer patients and healthy controls using a de novo proteomic approach［J］.Oncol Rep，2012，28（2）：429-438.
［31］ JEMAL A，BRAY F，CENTER MM，FERLAY J，WARD E，FORMAN D.Global cancer statistics［J］.CA Cancer J Clin，2011，61（2）：69-90.
［32］ ALONSO A，JICK SS，OLEK MJ，HERNAN MA.Incidence of multiple sclerosis in the United Kingdom：findings from a population-based cohort［J］.J Neurol，2007，254（12）：1736-1741.
［33］ VIRTANEN JO，WOHLER J，FENTON K，REICH DS，JACOBSON S.Oligoclonal bands in multiple sclerosis reactive against two herpesviruses and association with magnetic resonance imaging findings［J］.Mult Scler，2014，20（1）：27-34.
［34］ OBAL I，KLAUSZ G，MANDI Y，DELI M，SIKLOS L，ENGELHARDT JI.Intraperitoneally administered IgG from patients with amyotrophic lateral sclerosis or from an immune-mediated goat model increase the levels of TNF-α，IL-6，and IL-10 in the spinal cord and serum of mice［J］.J Neuroinflammation，2016，13（1）：1-12.
［35］ PHILLIPS TE，SHARP J，RODGERS K，LIU H.M cell-targeted ocular immunization：effect on immunoglobulins in tears，feces，and serum［J］.Invest Ophthalmol Vis Sci，2010，51（3）：1533-1539.
［36］ KAUSHIK DK，YONG HY，HAHN JN，SILVA C，CASHA S，HURLBERT RJ，et al.Evaluating soluble EMMPRIN as a marker of disease activity in multiple sclerosis：studies of serum and cerebrospinal fluid［J］.PLoS One，2016，11（10）：e0163802.
［37］ LEBRUN C，FORZY G，COLLONGUES N，COHEN M，DE SEZE J，HAUTECOEUR P，et al.Tear analysis as a tool to detect oligoclonal bands in radiologically isolated syndrome［J］.Rev Neurol（Paris），2015，171（4）：390-393.
［38］ SALVISBERG C，TAJOURI N，HAINARD A，BURKHARD PR，LALIVE PH，TURCK N.Exploring the human tear fluid：discovery of new biomarkers in multiple sclerosis［J］.Proteomics Clin Appl，2014，8（3-4）：185-194.
［39］ JANKOVIC J.Parkinson’s disease：clinical features and diagnosis［J］.J Neurol Neurosurg Psychiatry，2008，79（4）：368-376.
［40］ CERAVOLO R，PAGNI C，TOGNONI G，BONUCCELLI U.The epidemiology and clinical manifestations of dysexecutive syndrome in Parkinson’s disease［J］.Front Neurol，2012，3（3）：159.
［41］ PACHOULAKIS I，XILOURGOS N，PAPADOPOULOS N，ANALYTI A.A kinect-based physiotherapy and assessment platform for parkinson’s disease patients［J］.J Med Eng，2016，2016（4）：1-8.
［42］ OMO G¨LU SS，GVEN H，ACAR M，ZTRK G，KOER B.Tear levels of tumor necrosis factor-alpha in patients with Parkinson’s disease［J］.Neurosci Lett，2013，553（10）：63-7.
［43］ BRGER M，FUNKE S，BHR M，GRUS F，LINGOR P.Biomarker sources for Parkinson’s disease：time to shed tears［J］?Basal Ganglia，2015，5（2）：63-69.
［44］ GOLUBNITSCHAJA O，COSTIGLIOLA V，EPMA..General report & recommendations in predictive，preventive and personalised medicine 2012：white paper of the European Association for Predictive，Preventive and Personalised Medicine［J］.EPMA J，2012，3（1）：14.
相似文献/References:
[1]曾庆延 蒋华 牛晓光 吴尚操 喻长泰.单纯疱疹病毒性角膜炎患者双眼泪液功能改变[J].眼科新进展,2012,32(5):000.
[2]袁牧之,林颖,刘泉.视网膜静脉阻塞患者血浆和泪液中血管内皮生长因子表达的研究[J].眼科新进展,2016,36(5):468.[doi:10.13389/j.cnki.rao.2016.0125]
YUAN Mu-Zhi,LIN Ying,LIU Quan.Expression of VEGF in plasma and tears of patients with RVO[J].Recent Advances in Ophthalmology,2016,36(8):468.[doi:10.13389/j.cnki.rao.2016.0125]
[3]王蕊,李岩,高建民,等.干眼患者泪膜及睑板腺功能分析[J].眼科新进展,2016,36(12):1145.[doi:10.13389/j.cnki.rao.2016.0305]
WANG Rui,LI Yan,GAO Jian-Min,et al.Assessment of tear film and meibomian gland function in dry eye patients[J].Recent Advances in Ophthalmology,2016,36(8):1145.[doi:10.13389/j.cnki.rao.2016.0305]
[4]曾孝宇,赵少贞.糖尿病患者泪液及泪膜变化的研究进展[J].眼科新进展,2017,37(11):1097.[doi:10.13389/j.cnki.rao.2017.0277]
ZENG Xiao-Yu,ZHAO Shao-Zhen.Research progress on tear in patients with diabetes mellitus[J].Recent Advances in Ophthalmology,2017,37(8):1097.[doi:10.13389/j.cnki.rao.2017.0277]
[5]李筱荣,石怡.黄斑中心凹无血管区在眼部疾病中的临床意义[J].眼科新进展,2020,40(5):401.[doi:10.13389/j.cnki.rao.2020.0093]
LI Xiaorong,SHI Yi.Clinical significance of foveal avascular zone in ocular diseases[J].Recent Advances in Ophthalmology,2020,40(8):401.[doi:10.13389/j.cnki.rao.2020.0093]
[6]董敬红,薛嘉睿,张荣荣,等.病理性近视眼影像学生物标志物的研究现状[J].眼科新进展,2022,42(5):413.[doi:10.13389/j.cnki.rao.2022.0084]
DONG Jinghong,XUE Jiarui,ZHANG Rongrong,et al.Update of imaging biomarkers of pathological myopia[J].Recent Advances in Ophthalmology,2022,42(8):413.[doi:10.13389/j.cnki.rao.2022.0084]
[7]王玲,樊芳,贾志旸.原发性青光眼生物标志物的研究进展[J].眼科新进展,2022,42(6):495.[doi:10.13389/j.cnki.rao.2022.0101]
WANG Ling,FAN Fang,JIA Zhiyang.Advances in the study of biomarkers of primary glaucoma[J].Recent Advances in Ophthalmology,2022,42(8):495.[doi:10.13389/j.cnki.rao.2022.0101]
[8]张浩,赵婧,葛小宁,等.甲状腺相关性眼病的诊断性生物标志物研究进展[J].眼科新进展,2022,42(7):562.[doi:10.13389/j.cnki.rao.2022.0115]
ZHANG Hao,ZHAO Jing,GE Xiaoning,et al.Research progress in diagnostic biomarkers for thyroid-associated ophthalmopathy[J].Recent Advances in Ophthalmology,2022,42(8):562.[doi:10.13389/j.cnki.rao.2022.0115]